HC Wainwright & Co. Maintains Neutral on Zymeworks, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns maintains a Neutral rating on Zymeworks (NASDAQ:ZYME) and raises the price target from $8 to $10.
March 11, 2024 | 10:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Neutral rating on Zymeworks but increases the price target from $8 to $10.
The increase in price target from $8 to $10 by a reputable analyst firm like HC Wainwright & Co. suggests a positive outlook on Zymeworks' valuation, potentially leading to increased investor interest and a positive short term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100